Peregrine Pharmaceuticals reported $180.64M in Current Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Agenus AGEN:US $ 288.93M 1.55M
Amgen AMGN:US $ 19322M 802M
AstraZeneca AZN:LN 20.92B 1.73B
Bristol Myers Squibb BMY:US $ 30186M 65M
Celldex Therapeutics CLDX:US $ 367.98M 22.72M
Chemocentryx CCXI:US $ 345.17M 6.46M
Eli Lilly And LLY:US $ 17115.2M 150.5M
GlaxoSmithKline GSK:LN 5418.8B 2520B
Immunogen IMGN:US $ 373.87M 82.84M
Intrexon XON:US $ 164.62M 9.68M
Karyopharm Therapeutics KPTI:US $ 242.45M 34.09M
Macrogenics MGNX:US $ 167.63M 50.57M
Mannkind MNKD:US $ 193.48M 9.21M
Minerva Neurosciences NERV:US $ 50.04M 5.66M
Newlink Genetics NLNK:US 84.99M 7.66M
Novartis NOVN:VX 38.14B 906M
Novavax NVAX:US $ 2136M 211.4M
Peregrine Pharmaceuticals PPHM:US $ 180.64M 0.61M
Repligen RGEN:US $ 976M 31.21M
Xencor XNCR:US $ 585.94M 79.97M